Lexeo Therapeutics (LXEO) Restructuring Costs (2024 - 2026)

Lexeo Therapeutics (LXEO) has 3 years of Restructuring Costs data on file, last reported at $4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Restructuring Costs fell 62.52% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $29.1 million (down 10.78% YoY), and the FY2025 full-year result was $37.0 million, up 48.06% from the prior year.
• Restructuring Costs fell to $4.7 million in Q1 2026, from $9.3 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $12.6 million in Q1 2025 to a low of $2.9 million in Q3 2025.
• A 3-year average of $7.4 million and a median of $4.9 million in 2024 frame the typical range for Restructuring Costs.
• Across the five-year window, Restructuring Costs surged 209.04% in 2025 and slumped 62.52% in 2026, its largest moves.
• Tracing LXEO's Restructuring Costs over 3 years: stood at $11.8 million in 2024, then declined by 21.02% to $9.3 million in 2025, then slumped by 49.47% to $4.7 million in 2026.
• Business Quant data shows LXEO's Restructuring Costs at $4.7 million in Q1 2026, $9.3 million in Q4 2025, and $2.9 million in Q3 2025.